Financial reports
ARS
2023 FY
Annual report to shareholders
26 Apr 24
10-K
2023 FY
Annual report
7 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
10-Q
2023 Q1
Quarterly report
9 May 23
ARS
2022 FY
Annual report to shareholders
27 Apr 23
10-K
2022 FY
Annual report
14 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
10-Q
2022 Q1
Quarterly report
10 May 22
Current reports
8-K
Other Events
9 Apr 24
8-K
Departure of Directors or Certain Officers
20 Mar 24
8-K
Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
7 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
17 Nov 23
8-K
Viracta Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
9 Nov 23
8-K
Viracta Therapeutics to Host R&D Day Highlighting Nana-val in Epstein-Barr Virus (EBV)-Associated Cancers
4 Oct 23
8-K
Viracta Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
14 Aug 23
8-K
Viracta Therapeutics Appoints Darrel P. Cohen, M.D., Ph.D. as Chief Medical Officer
7 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
9 Jun 23
8-K
Viracta Therapeutics Reports First Quarter 2023 Financial Results and Provides Clinical Program Updates
8 May 23
Registration and prospectus
S-8
Registration of securities for employees
7 Mar 24
S-8
Registration of securities for employees
14 Mar 23
S-8
Registration of securities for employees
27 Jun 22
S-8
Registration of securities for employees
18 Mar 22
S-3
Shelf registration
28 May 21
S-8
Registration of securities for employees
2 Apr 21
425
Business combination disclosure
16 Feb 21
425
Business combination disclosure
12 Feb 21
425
Business combination disclosure
11 Feb 21
424B3
Prospectus supplement
14 Jan 21
Proxies
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
DEF 14A
Definitive proxy
27 Apr 23
DEFA14A
Additional proxy soliciting materials
27 Apr 23
DEFA14A
Additional proxy soliciting materials
27 Apr 22
DEF 14A
Definitive proxy
27 Apr 22
DEFA14A
Additional proxy soliciting materials
28 Apr 20
DEF 14A
Definitive proxy
28 Apr 20
PRE 14A
Preliminary proxy
17 Apr 20
DEFA14A
Additional proxy soliciting materials
12 Apr 19
Other
EFFECT
Notice of effectiveness
7 Jun 21
CORRESP
Correspondence with SEC
2 Jun 21
UPLOAD
Letter from SEC
2 Jun 21
EFFECT
Notice of effectiveness
15 Jan 21
CORRESP
Correspondence with SEC
12 Jan 21
UPLOAD
Letter from SEC
29 Dec 20
CT ORDER
Confidential treatment order
18 Mar 19
CT ORDER
Confidential treatment order
18 Mar 19
EFFECT
Notice of effectiveness
21 Nov 17
CORRESP
Correspondence with SEC
17 Nov 17
Ownership
3
Melody Burcar
22 Mar 24
4
Mark Rothera
13 Mar 24
4
Darrel P. Cohen
13 Mar 24
4
Daniel R. Chevallard
13 Mar 24
144
Notice of proposed sale of securities
27 Feb 24
4
IVOR ROYSTON
27 Feb 24
4
Roger Pomerantz
27 Feb 24
4
Daniel R. Chevallard
27 Feb 24
SC 13G
FORWARD VENTURES V LP
13 Feb 24
4
Mark Rothera
4 Dec 23